Skip to main content

Table 2 Annual costs in Euros for non-metastatic and metastatic to bone prostate cancer patients with biochemical recurrence

From: Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

Cost item

Patients without bone metastases (n = 48)

Patients with bone metastases (n = 7)

Androgen deprivation therapy

523 (364–695)

691 (244–1165)

Hospitalisation costs

 First year (with salvage radiation therapy)

2601 (1376–4381)

3706 (491–8138)

 Other years

921 (431–1510)

3706 (631–7973)

Total costs

 First year

3524 (2277–5246)

4816 (1615–9234)

 Subsequent years

1844 (1354–2434)

4815 (1689–9308)

  1. Mean annual treatment/management costs with 95% confidence interval. Total costs included hospitalization costs, monitoring costs (office visit, biology and imaging) and drugs costs